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Pancreatic ductal adenocarcinoma (PDA) is a lethal malignancy with limited treatment
options. Although metabolic reprogramming is a hallmark of many cancers, including PDA,
previous attempts to target metabolic changes therapeutically have been stymied by drug
toxicity and tumour cell plasticity. Here, we show that PDA cells engage an eIF4F-dependent
translation program that supports redox and central carbon metabolism. Inhibition of the
eIF4F subunit, eIF4A, using the synthetic rocaglate CR-1-31-B (CR-31) reduced the viability of
PDA organoids relative to their normal counterparts. In vivo, CR-31 suppresses tumour
growth and extends survival of genetically-engineered murine models of PDA. Surprisingly,
inhibition of eIF4A also induces glutamine reductive carboxylation. As a consequence,
combined targeting of eIF4A and glutaminase activity more effectively inhibits PDA cell
growth both in vitro and in vivo. Overall, our work demonstrates the importance of eIF4A
in translational control of pancreatic tumour metabolism and as a therapeutic target
against PDA.
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Pancreatic ductal adenocarcinoma (PDA), a highly aggres-sive malignancy with limited treatment options, is now thethird leading cause of cancer death in the United States1.
Most PDA patients share common pathogenic lesions, including
a high frequency of oncogenic KRAS mutations (90–95%) and the
inactivation of certain tumour suppressors, such as TP53, P16/
INK4A, and SMAD42,3. Indeed, genetically-engineered mouse
models (GEMMs) of PDA harbouring the KrasLSL-G12D,
Trp53LSL-R172H, and Pdx1-cre (KPC) alleles recapitulate the
complex histopathological features of human PDA4. Nonetheless,
due to its low neoplastic cellularity, it remains challenging to
study the molecular mechanisms underlying PDA. Using a three-
dimensional organoid culture system that allows direct compar-
ison between primary tumour cells and their normal, proliferating
counterparts5, we previously showed that PDA is dependent on a
KRAS-mediated increase in protein synthesis6. However, the
repertoire of mRNAs that are translationally altered by oncogenic
KRAS signalling remains unknown.
In most human cancers, the oncogenic signalling pathways that
promote tumorigenesis also act to dysregulate protein synthesis7.
For example, the PI3K/AKT/mTOR and MEK/Mnk signalling
pathways both converge on eukaryotic initiation factor 4F (eIF4F)
to promote cap-dependent mRNA translation7,8. It is widely
acknowledged that a rate-limiting step of cap-dependent trans-
lation is the assembly of an active eIF4F complex7, high levels of
which correlate with poor prognosis and drug resistance in var-
ious cancers7,9. eIF4F is a heterotrimeric complex consisting of
the cap-binding protein eIF4E, the large scaffolding protein
eIF4G, and the DEAD-box RNA helicase eIF4A10. The eIF4A
helicase is required to unwind cap-proximal secondary structures
within the mRNA 5′-UTR during scanning as a prelude to its
association with the 43S preinitiation complex, in an ATP-
dependent fashion11.
Given the diversity of downstream AKT/mTOR effectors,
previous attempts to suppress translation in cancer cells ther-
apeutically by targeting this pathway have yielded adverse phe-
notypes, such as compensatory increases in MAP kinase12 or
receptor tyrosine kinase signalling13. Moreover, inhibition of
mTORC1 using rapamycin leads to increased pancreatic tumor-
igenesis through the induction of extracellular protein uptake14.
Therefore, direct targeting of the eIF4F complex has recently
emerged as an attractive antineoplastic strategy. It is well estab-
lished that the helicase activity of eIF4A is the predominant target
of the rocaglates, a family of translation inhibitors that harbour a
common cyclopenta[b]benzofuran skeleton produced exclusively
by the Aglaia genus of angiosperms15–19. Here, we show that
PDA organoids exhibit heightened sensitivity to the rocaglate CR-
1-31-B (CR-31) relative to normal, proliferating ductal organoids.
In addition, polysome proﬁling identiﬁed an oncogenic transla-
tion program in PDA organoids comprised of mRNAs involved
in redox and central carbon metabolism. Indeed, we observe an
increase in both glycolysis and oxidative phosphorylation in PDA
organoids compared to their normal counterparts. Moreover, by
disrupting this translation program, treatment of PDA cells with
CR-31 induces an energy crisis and cell death. In vivo, CR-31
suppresses pancreatic cancer cell growth and improves the sur-
vival of pancreatic tumour-bearing mice. Thus, our study
uncovers a previously unrecognized role for translation in PDA
metabolic reprogramming, and provides a framework for tar-
geting tumour-speciﬁc translation programs in the clinic.
Results
eIF4A is a therapeutic target in PDA. We previously showed
that protein synthesis is elevated in pancreatic cancer cells in a
redox-dependent manner6. Indeed, using a non-isotopic method
to measure total in vivo protein synthesis (SUnSET)20, we
observed markedly increased labelling of pancreatic ductal car-
cinoma cells relative to normal ductal cells (Supplementary
Fig. 1a). Using murine pancreatic organoid cultures grown from
ductal isolates of wildtype, normal (N), and KrasG12D;p53R172H-
bearing tumour (KP) tissues5,6, we also detected elevated incor-
poration of O-propargyl-puromycin (OP-puro)21 into nascent
polypeptides after a 30 min pulse in KP compared to N organoids
(Supplementary Fig. 1b). Thus, protein synthesis is hyperactive in
both organoid and in vivo models of PDA. These observations
support the notion that cancer cells require an aberrantly acti-
vated translational state for survival and suggest that targeting
translation might provide a favourable therapeutic index for
pancreatic cancer22. To explore this possibility in PDA, we
evaluated selective inhibition of the DEAD-box RNA helicase,
eIF4A, using the rocaglate, CR-31 (Supplementary Fig. 1c)16.
Consistent with previous studies of rocaglates16,23,24, CR-31
substantially decreases the off-rate of eIF4A from polypurine-
RNAs in the presence of ATP or AMP-PNP (Supplementary
Fig. 1d), thus conﬁrming its inhibitory effect on eIF4A. When N
and KP organoids were treated with CR-31 for 1 h, we found that
N organoids were minimally affected (Fig. 1a), while a striking
dose-dependent decrease in nascent protein synthesis was
observed in KP organoids as measured by either [35S]-methionine
(Supplementary Fig. 1e) or OP-puro (Fig. 1a) incorporation.
Consistent with this observation, KP organoids exhibit higher
sensitivity to CR-31 compared to N organoids in viability
assays (Fig. 1b, Supplementary Fig. 1f), with a 10 fold decrease
in half maximal inhibitory concentration (IC50) (Supplementary
Figs. 1f, g). CR-31 is also cytotoxic towards a panel of patient-
derived PDA cell lines, with similar IC50 values (Supplementary
Fig. 1g, h). These results suggest that CR-31 is a potent inhibitor
of PDA protein synthesis and survival in vitro.
Encouraged by our in vitro observations, we tested the effects
of CR-31 using a murine orthotopic transplant model of PDA.
When tumour diameters reached 7–9 mm by ultrasound imaging,
mice were randomly assigned into treatment groups with either
CR-31 or vehicle, following a dosage regimen previously reported
to exert no toxicity towards cells of hematopoietic origin16. At
this dose, CR-31 effectively inhibited protein synthesis (Fig. 1c)
and growth (Fig. 1d) of pancreatic tumours. The effect of CR-31
was cytotoxic instead of cytostatic, as evidenced by a 5 fold
increase in immuno-staining of cleaved caspase 3 (Fig. 1e) but not
phospho-histone H3 (Supplementary Figs. 1i, j). Importantly, this
dosage regimen did not induce measurable changes in body
weight (Supplementary Fig. 2a) or in circulating levels of liver
(Supplementary Fig. 2b) or pancreatic (Supplementary Fig. 2c)
enzymes. Gender-balanced cohorts of non-tumour-bearing
C57Bl/6J mice given the same treatment for 12 days also
displayed no changes in body weight (Supplementary Fig. 2d),
circulating levels of liver enzymes (Supplementary Fig. 2e) or
tissue histology (Supplementary Fig. 2f). In contrast to pancreatic
tumours (Fig. 1e), CR-31 treatment did not induce caspase 3
cleavage in the healthy pancreas even after 12 days of treatment
(Supplementary Fig. 2g). Finally, in the autochthonous KPC
model4, CR-31 improved survival compared to vehicle-treated
controls (Fig. 1f). Collectively, these results suggest that CR-31-
mediated eIF4A inhibition can suppress PDA growth without
inducing measurable systemic toxicity in vivo. eIF4A may
therefore represent an attractive therapeutic target for PDA.
CR-31 modulates mRNA-selective translation in PDA. We next
sought to decipher the mechanisms underlying the enhanced
sensitivity of PDA to CR-31. Given that the PI3K/AKT/mTOR
and MEK/MNK/eIF4E signalling pathways can regulate both
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global and mRNA-selective translation via modulation of eIF4F-
complex formation25–27, we ﬁrst examined whether signalling
through these pathways can be modulated by CR-31 treatment.
We did not observe quantitative decreases in the phosphorylation
status of proteins in the PI3K (AKT, mTOR, S6, 4EBP) and MEK
(eIF4E) cascades in either murine (Supplementary Fig. 3a, b, d) or
human (Supplementary Fig. 3c) PDA cells after 1 h or 5 h of CR-
31 treatment. Interestingly, N organoids exhibited an increase in
phospho-S6 at both time points, but without a corresponding
change in phospho-4EBP1 levels (Supplementary Fig. 3a, d). We
also noted a transient induction of eIF4E phosphorylation in CR-
31-treated KP organoids which subsided at 5 h post treatment
(Supplementary Fig. 3b, d), though these changes were not
observed in patient-derived PDA cell lines (Supplementary
Fig. 3c). These results indicate that inhibition of translation upon
CR-31 treatment is not due to an indirect suppression of the
PI3K/AKT/mTOR or MEK/MNK/eIF4E signalling pathways.
Notably, acute CR-31 treatment did not induce phosphorylation
of eIF2α (Supplementary Fig. 3e), thereby precluding a primary
role for the integrated stress response in CR-31-mediated sup-
pression of translation28.
The eIF4F complex sits at the junction of several potent
oncogenic pathways including, most notably, c-MYC. As
translation of c-MYC mRNA is highly eIF4F-dependent7, we
asked whether the cytotoxic effect of CR-31 on pancreatic
tumours in vivo is due to a reduction of c-MYC expression. While
CR-31 treatment suppresses tumour growth in vivo (Fig. 1d),
these tumours, collected 2 h after ﬁnal treatment, do not exhibit a
decrease in c-MYC protein levels (Supplementary Fig. 3f). Thus,
we reasoned that reduced c-MYC expression is not a driver of the
tumour suppressive activity of CR-31 in PDA cells. Therefore, we
asked whether selective alterations in the translation efﬁciency of
other transcripts might underlie the observed differences in
response to CR-31. To this end, we performed polysome proﬁling
to compare the effects of CR-31 on the translatomes (i.e., the pool
of efﬁciently translated mRNAs) of N and KP organoids
(Supplementary Fig. 4a). During polysome proﬁling, efﬁciently
translated mRNAs (associated with ≥3 ribosomes) were isolated
and quantiﬁed. Anota2seq29 was used to compare the changes in
polysome-associated mRNAs to the total transcript levels of each
mRNA. Given that altered levels of total mRNA will also impact
the pool of polysome-associated mRNA, this allows the
identiﬁcation of bona ﬁde changes in translation efﬁciency.
Through this analysis, we identiﬁed strong differences between
the translatomes of vehicle-treated N and KP organoids (Fig. 2a).
Consistent with the oncogenic activity of the eIF4F complex in
cancer cells, transcripts previously shown to exhibit eIF4E-
dependent translation30 (eIF4E-signature) are translationally
activated in KP relative to N organoids (Supplementary Fig. 4b).
Interestingly, while CR-31 treatment has minimal impact on the
N translatome (Fig. 2b, Supplementary Data 1), it induces marked
changes in the KP translatome (Fig. 2c, Supplementary Data 2).
Consistently, the eIF4E-signature is translationally suppressed by
CR-31 only in KP (Supplementary Fig. 4c), but not in N
organoids (Supplementary Fig. 4d). Strikingly, upon CR-31
treatment, the subset of mRNAs that are translationally activated
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Fig. 1 The eIF4A inhibitor CR-31 potently targets pancreatic ductal adenocarcinoma. a Normal (N), and KrasG12D;p53R172H (KP) organoids were treated with
10 nM CR-31 for 60min and compared to vehicle (DMSO). During the last 30min, 10 μM O-propargyl-puromycin (OP-Puro) was supplemented into the
media. Dissociated single cells were ﬁxed, stained by CuAAC with Alexa488-azide and the level of OP-Puro conjugation within polypeptide chains was
quantiﬁed by ﬂow cytometry. b Cell viability of N and KP organoids upon a 72 h treatment with increasing concentrations of CR-31. Dotted lines indicate
95% conﬁdence intervals (n= 5). Inset shows representative images of organoids treated with 10 nM CR-31 for 72 h. Scale bars, 1000 μm. c SUnSET assay
of representative PDA tumours from mice following 7 daily treatments with vehicle (5.2% PEG-400/5.2% Tween80) or 0.2 mg kg−1 CR-31. Mice were
euthanized for tissue collection 2 h after the ﬁnal treatment with vehicle or CR-31 and 30min after 40 nmol g−1 puromycin injection. Scale bars, 50 μm.
d Relative tumour volume of PDA-bearing mice after 7 daily treatments with 0.2 mg kg−1 CR-31 or vehicle. Relative growth was estimated by comparison of
tumour volume 7 days post injection to that at pre-enrolment (day 0) by ultrasound imaging. Data are mean +/– S.D. Student’s t-test. (n= 11, vehicle; n=
7, CR-31). e Immunohistochemistry of cleaved caspase 3 (left) in representative tumours from mice treated daily for 7 days with vehicle or 0.2 mg kg−1 CR-
31 together with quantiﬁcation of cleaved caspase 3 (right) from n≥ 7 ﬁelds of view. Data are mean +/–S.D. Student’s t-test. Tissues were harvested 2 h
post ﬁnal treatment. Scale bars, 50 μm. f Kaplan–Meier survival analysis for KrasG12D;p53R172H;PdxCre (KPC) mice treated daily with vehicle (n= 13) or
0.2 mg kg−1 CR-31 (n= 16). Mantel-Cox (log rank) test. Source data are provided as a Source Data ﬁle
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Fig. 2 Tumour-selective modulation of translational efﬁciencies by CR-31. a Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes
comparing vehicle-treated KrasG12D;p53R172H (KP) to normal (N) organoids. The numbers of mRNAs with a change in translation efﬁciency (light red and
dark red) or mRNA abundance (light green and dark green) are indicated (n= 3; positive log2 fold-change indicates higher translation/abundance in KP
organoids). b Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes comparing N organoids treated with vehicle or 10 nM CR-31 for
1 h. The numbers of mRNAs with a change in translation efﬁciency (light red and dark red) are indicated (negative log2 fold-change indicates suppressed
translation upon CR-31 treatment). c Scatterplot of polysome-associated mRNA to total mRNA log2 fold-changes comparing KP organoids treated with
vehicle or 10 nM CR-31 for 1 h. The numbers of mRNAs with a change in translation efﬁciency (light red and dark red) are indicated (negative log2 fold-
changes indicates suppressed translation upon CR-31 treatment). d Scatterplot of log2 fold-changes for polysome-associated mRNA and total mRNA (left),
an empirical cumulative distribution (ecdf) of log2 fold-changes for polysome-associated mRNA (middle) and total mRNA (right) comparing KP and N
organoids. Transcripts whose translation was activated (light red) or suppressed (dark red) upon CR-31 treatment in KP organoids (i.e. from (c)) are
indicated for each plot. Wilcoxon rank-sum test p-values comparing regulation of subsets to background are indicated together with the log2 fold-changes
difference between these subsets to the background at the 50th percentile (q50) of the ecdf. e Same representation as in panel d but examining
differences in gene expression in N organoids upon CR-31 treatment. Source data are provided as a Source Data ﬁle
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in KP relative to N organoids revert towards their translational
state in N organoids, such that the translatome of CR-31-treated
KP organoids resembles that of vehicle-treated N organoids
(Fig. 2d, Supplementary Data 3). In contrast, translation of this
mRNA subset is unaffected upon CR-31 treatment in N
organoids (Fig. 2e). In line with our earlier observation, c-MYC
is not amongst the mRNAs that are sensitive to CR-31 in N or KP
organoids.
Factors required for efﬁcient translation of an mRNA are
determined in large part by diverse features of its 5′ untranslated
region (UTR), including its length, secondary structure, and
sequence motifs. Therefore, we next sought to identify RNA
features associated with the effects of CR-31 on mRNA
translation. Consistent with a recent report examining the 5′-
UTRs of eIF4A-dependent mRNAs31, we did not observe an
enrichment for (GGC)4 motifs, which are proposed to fold into
G-quadruplexes, within the 5’-UTRs of mRNAs whose transla-
tion is suppressed by CR-31 (Supplementary Fig. 5a). We also did
not observe an enrichment for polypurines24 in the 5′-UTRs of
transcripts that are translationally suppressed in KP organoids
after CR-31 treatment (Supplementary Fig. 5b). Instead, we found
that transcripts which are negatively regulated by CR-31
treatment have slightly shorter 5′-UTRs (Supplementary Fig. 5c),
exhibit an elevated GC content (Supplementary Fig. 5d), and are
more structured (after adjustment of fold-energies for 5′-UTR
lengths) than non-regulated transcripts (Supplementary Fig. 5e).
Thus, the RNA helicase eIF4A supports an oncogenic translation
program that is activated in pancreatic cancer cells and
characterized by mRNAs with structured 5′-UTRs. Overall, our
results indicate that while inhibition of eIF4A by CR-31 exhibits
minimal impact on the translatome of N organoids, it effectively
reprograms the translatome of KP organoids towards that of N
organoids.
PDA cells enhance translation of redox metabolism enzymes.
To determine whether the subset of proteins whose synthesis is
targeted by CR-31 in KP organoids represents particular bio-
chemical processes, we performed KEGG pathway enrichment
analysis using the gage R package32. Consistent with a previous
study showing that eIF4E is critical for selective translation of
mRNAs that control intracellular levels of reactive oxygen species
(ROS) during cellular transformation33, we observed translational
activation of mRNAs involved in glutathione metabolism in KP
relative to N organoids (Fig. 3a, Supplementary Fig. 6). Impor-
tantly, the translation of several of these mRNAs is selectively
downregulated in KP organoids upon CR-31 treatment (Fig. 3a,
Supplementary Fig. 6). These results suggest that maintenance of
redox homeostasis is an oncogenic activity of the eIF4F complex
that can be targeted using CR-31.
The ratio of the ROS scavenger glutathione (GSH) to its
oxidized form (GSSG) is a marker of oxidative stress. We found
that several key enzymes involved in glutathione synthesis, as well
as the production of NADPH (the cofactor that supports
regeneration of GSH from GSSG), are translationally induced in
KP organoids, and suppressed upon CR-31 treatment (Fig. 3a).
Indeed, CR-31 treatment led to a signiﬁcant decrease in NADPH,
and a corresponding increase in the ratio of NADP+ to NADPH
in KP, but not N (Fig. 3b) organoids. Similar responses were
observed in patient-derived PDA cell lines (Fig. 3b). Treatment of
these PDA lines with CR-31 also led to a dose-dependent decrease
in total GSH levels (Fig. 3c) and in the ratio of GSH to GSSG
(Fig. 3d). Likewise, CR-31 treatment moderately increased the
levels of ROS in KP organoids (Fig. 3e). The increase in ROS was
also indicated by the accumulation of Nuclear factor erythroid-
derived 2-like 2 (NFE2L2/NRF2), a central regulator of redox
control34 (Fig. 3f), and transactivation of its downstream target
genes (Fig. 3g). While genetic ablation of Nrf2 did sensitize KP
organoids to CR-31 treatment (Fig. 3h), direct inhibition of
glutathione synthesis using buthionine sulfoximine (BSO) did not
phenocopy the effect of Nrf2 ablation (Fig. 3i). The ROS
scavenger N-acetyl-cysteine (NAC) also failed to alleviate the
cytotoxicity of CR-31 in these cells (Fig. 3j). Thus, although eIF4A
inhibition using CR-31 perturbs redox homeostasis, the cytotoxic
effect of CR-31 is unlikely to be mediated by redox dysregulation.
PDA translation program supports central carbon metabolism.
Relative to the translatome of N organoids, we found that the
most highly translated mRNAs in KP organoids encode proteins
involved in oxidative phosphorylation (Supplementary Fig. 6). In
fact, almost every protein component of the electron transport
chain (ETC) is encoded by transcripts that are translationally
activated in KP organoids (Fig. 4a), despite no apparent changes
in mRNA levels (Fig. 4b). For example, expression of the Sdhb
protein, a subunit in complex II, is upregulated in KP relative to
N organoids (Supplementary Fig. 7a). In accordance with the
translational activation of mRNAs encoding ETC components in
KP organoids, we observed that at steady state, oxidative phos-
phorylation is elevated in KP relative to N organoids, as deter-
mined by the rate of mitochondrial oxygen consumption (OCR)
(Supplementary Fig. 7b) and the percentage contribution of
uniformly-labelled 13C6-glucose into citrate in the TCA cycle
(Fig. 4c). Strikingly, KEGG pathway analysis shows that the
translation of ETC transcripts is suppressed by CR-31 in KP
organoids (Fig. 4a, Supplementary Fig. 6). We further conﬁrmed
by quantitative RT-PCR that mRNAs encoding proteins in
complex I and II (Ndufa3 and Sdhb) show decreased polysome
association in CR-31-treated KP organoids (Supplementary
Fig. 7c). Although mitochondrial numbers are largely unaffected
by CR-31 treatment, as determined by MitoTracker Green
staining (Supplementary Fig. 7d), OCR was markedly decreased
in a dose-dependent manner upon 5 h of CR-31 treatment in
both KP organoids (Fig. 4d) and patient-derived PDA cell lines
(Supplementary Fig. 7e), but to a much lower extent in N orga-
noids (Fig. 4e). The resultant energy stress is also evident from the
induction of phospho-AMPK in KP organoids (Supplementary
Fig. 7f). In accordance with the polysome proﬁling data,
expression of the Saccharomyces cerevisiae NADH dehydrogenase
(ETC complex I) NDI135 only partially rescued CR-31-induced
suppression of oxidative phosphorylation in PDA cells (Supple-
mentary Fig. 7g), indicating that CR-31 impacts multiple com-
plexes of the ETC (Fig. 4a). Importantly, shRNA-mediated
depletion of eIF4A1 also suppressed oxidative phosphorylation in
both murine (Supplementary Fig. 7h) and human (Supplemen-
tary Fig. 7i) PDA cells, conﬁrming that the availability of eIF4A1
plays a role in the regulation of oxidative phosphorylation.
Defective oxidative phosphorylation is expected to induce a
metabolic shift towards aerobic glycolysis. As a consequence, cells
treated with inhibitors of oxidative phosphorylation generally
exhibit a heightened sensitivity to glucose deprivation36. How-
ever, we observed that PDA cells were not more sensitive to CR-
31 under low glucose conditions (Supplementary Fig. 8a). This
prompted us to investigate the impact of eIF4A inhibition on
glycolysis in greater detail. Comparing N and KP organoids, we
observed that KP organoids exhibit elevated levels of glycolysis, as
determined by the extracellular acidiﬁcation rate (ECAR)
(Supplementary Fig. 8b) and the contribution of uniformly-
labelled 13C6-glucose to lactate after 2 h of culture in 13C6-glucose
(Supplementary Fig. 8c). The relative partitioning of glucose label
between citrate in the TCA cycle and lactate, as determined by the
ratio of lactate M+ 3 to citrate M+ 2, is also increased in KP
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organoids (Supplementary Fig. 8d). When KP organoids (Fig. 4f,
Supplementary Fig. 8e, f) or patient-derived PDA cells (Fig. 4f)
were treated with CR-31, global levels of intracellular and secreted
lactate were reduced. Interestingly, this effect was much more
potent in KP organoids than in N organoids (Fig. 4f). Consistent
with the reduction of glycolysis in CR-31-treated PDA cells, we
observed a decreased contribution of 13C6-glucose in all
detectable upstream intermediates of the glycolytic pathway
(Supplementary Fig. 8g). In an acute glycolytic stress test, CR-31
treatment for 5 h suppressed the ECAR of KP organoids (Fig. 4g)
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Fig. 3 CR-31 translationally targets glutathione metabolism in PDA. a Heatmap of glutathione metabolism pathway proteins (KEGG database) showing
fold-changes of polysome-associated mRNA. b Relative levels of NADPH normalized to viability based on CellTitre-Glo (CTG) assay (left) and ratio of
NADP+ to NADPH (right) in organoids and patient-derived PDA lines upon treatment with vehicle (DMSO) or 100 nM CR-31 for 16 h. Data are mean
+/–S.D. Student’s t-test, n= 4 (organoids), n= 5 (patient-derived lines). NS= not signiﬁcant. c Relative levels of glutathione in patient-derived PDA lines
upon treatment with vehicle or CR-31 for 24 h. Data are mean +/–S.D., Student’s t-test. n= 5, NS= not signiﬁcant. *p < 0.05 compared to DMSO
treatment. d Ratio of GSH to GSSG in patient-derived PDA lines upon treatment with vehicle or the indicated concentrations of CR-31 for 24 h. Data are
mean +/–S.D., Student’s t-test, n= 5. *p < 0.05 compared to DMSO treatment. e ROS levels in KP organoids upon treatment with vehicle or 10 nM CR-31
for 16 h. Data are representative from three biological replicates. f NRF2 protein levels in KP organoids treated with CR-31 for 16 h. Actin, loading control.
Representative image from 3 biological replicates. gmRNA expression of NRF2 target genes in 3 patient-derived PDA lines upon treatment with CR-31 for 5
or 24 h. Data are mean +/–S.D. Each data point plotted is average from every biological replicate. h Cell viability of KP and Nrf2-deﬁcient KP (KPn)
organoids upon a 72 h treatment with increasing concentrations of CR-31. Dotted lines indicate 95% conﬁdence intervals, n= 5. i Cell viability of patient-
derived PDA lines upon treatment with increasing concentrations of CR-31 in the presence or absence of 100 μM buthionine sulfoximine (BSO) for 72 h.
Data are mean +/–S.D., n= 5. j Cell viability of primary murine PDA lines upon treatment with increasing concentrations of CR-31 in the presence or
absence of 1 mM of the ROS scavenger N-acetylcysteine (NAC) for 72 h. Data are mean +/–S.D., n= 3. Source data are provided as a Source Data ﬁle
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Fig. 4 CR-31 translationally targets oxidative phosphorylation and glycolysis in PDA. a Heatmap of oxidative phosphorylation pathway proteins showing
fold-changes of polysome-associated mRNA. b Boxplots of total and polysome-associated mRNA levels for transcripts encoding oxidative phosphorylation
components. Horizontal line indicates the median; lower and upper box indicate the ﬁrst and third quartiles. Whiskers extend from the box to the most
extreme value but not further than +/−1.5 * inter-quartile range (IQR) from the box. Data exceeding the whiskers are plotted as points. b 13C6-glucose
tracing of N (n= 2) and KP organoids (n= 4). M +2 labelled citrate is derived directly from 13C6-glucose. Data are mean+/– S.D., Student’s t-test.
cMitochondrial respiration reﬂected by oxygen consumption rate (OCR) was measured in KP organoids treated with vehicle or CR-31 for 5 h and following
the addition of Oligomycin (1 μM), the uncoupler FCCP (0.5 μM), and the electron transport inhibitor Rotenone/Antimycin A (0.5 μM). Data are mean
+/– S.D, n= 3. Data are representative from three biological replicates. d OCR was measured in N organoids treated with vehicle CR-31 for 5 h and
following the addition of Oligomycin, FCCP, and Rotenone/Antimycin A. Data are mean+/– S.D. n= 5. Data are representative from three biological
replicates. e Top, ﬂow of heavy carbons through the glycolytic pathway. Bottom, 13C6-glucose tracing of two sets of N and KP organoids (left) and 4
patient-derived PDA cell lines (middle and right) upon treatment with vehicle or 100 nM CR-31 for 5 h. Data are mean+/– S.D., Student’s paired t-test.
f Glycolysis reﬂected by extracellular acidiﬁcation rate (ECAR) was measured in KP organoids treated with vehicle or CR-31 for 5 h and following addition of
glucose (10mM), Oligomycin (1 μM), and the glucose analog, 2-deoxyglucose, 2DG (50mM). Data are mean+/– S.D., n= 3. Data are representative of
three biological replicates. g ECAR was measured in N organoids treated with vehicle or CR-31 for 5 h and following addition of glucose, Oligomycin, and
2DG. Data are mean+/– S.D., n= 5. Data are representative of three biological replicates. Source data are provided as a Source Data ﬁle
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-13086-5 ARTICLE
NATURE COMMUNICATIONS |         (2019) 10:5151 | https://doi.org/10.1038/s41467-019-13086-5 | www.nature.com/naturecommunications 7
and patient-derived PDA cell lines (Supplementary Fig. 8h) in a
dose-dependent manner. CR-31 also impacted N organoids in an
acute glycolytic stress test, but to a lower extent (Fig. 4h).
Given the above observations, we ﬁrst examined the expression
levels of various glycolytic enzymes. Since CR-31 treatment up to
24 h did not consistently decrease the expression of these
enzymes at either the mRNA (Supplementary Fig. 9a) or the
protein level (Supplementary Fig. 9b), it is unlikely that CR-31
suppresses glycolysis by perturbing the expression of these
proteins. As oncogenic KRAS maintains PDA by regulating
anabolic glucose metabolism37,38, we also asked whether CR-31
impairs glycolysis by directly suppressing KRAS levels. However,
neither murine (Supplementary Fig. 10a, b) nor human
(Supplementary Fig. 10c, d) PDA cells exhibit a decrease in
KRAS expression level following CR-31 treatment. In fact, there
seems to be a transient induction of KRAS expression after 1 h of
CR-31 treatment, which subsides at later timepoints (Supple-
mentary Fig. 10a–d). Collectively, our data indicate that the
metabolic alterations occurring upon CR-31 treatment cannot be
attributed to suppression of either KRAS or the glycolytic
proteins examined.
Upon manual inspection of our polysome proﬁling data, we
found several enzymes involved in glucose transport and
metabolism to be targets of CR-31. For example, in KP organoids,
but not N organoids, a 1 h treatment with 10 nM CR-31 markedly
reduced the levels of polysome-associated mRNAs encoding the
glucose transporter Slc2a6, and the glycolytic enzymes GAPDH,
Enolase 2, and Enolase 3 (Fig. 5a). Of these, however, only the
SLC2A6 glucose transporter displayed a clear decrease in steady-
state protein levels after CR-31 treatment in KP organoids
(Fig. 5b, Supplementary Fig. 11a) and patient-derived PDA cell
lines (Fig. 5c). This is likely due to the relatively shorter half-life
of this transporter compared to the long-lived GADPH and
ENOLASE enzymes (Supplementary Fig. 11b). In accordance
with this observation, we found that CR-31 treatment decreased
glucose uptake in a dose-dependent fashion (Fig. 5d). These
results were validated in vivo by FDG-PET analysis of PDA
orthotopic transplants, which revealed a marked reduction in
tumour glucose uptake relative to muscle after CR-31 treatment
as compared to vehicle controls (Fig. 5e, f).
Elevated glucose uptake in cancer cells is traditionally
attributed to the glucose transporters SLC2A1 and SLC2A339.
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However, these transporters were not identiﬁed as CR-31-
sensitive transcripts by polysome proﬁling. Consistently, minimal
changes were observed in the expression of these transporters in
whole cell lysates (Supplementary Fig. 9b) and at the membrane
level (Supplementary Fig. 11c, d). We therefore asked if impaired
glucose metabolism in CR-31 treated cells might be attributed to
the less characterized glucose transporter, SLC2A6. To evaluate
the contribution of SLC2A6 to glucose uptake in PDA cells, we
perturbed Slc2a6 expression using two independent sgRNAs
(Supplementary Fig. 11e, f). Compared to cells expressing a
control sgRNA targeting the ROSA locus, sgSlc2a6 expression
decreased glucose uptake (Fig. 5g) and glycolysis in murine PDA
cell lines (Fig. 5h) and in KP organoids (Fig. 5i). Collectively, our
data suggest that CR-31 suppresses glycolysis in PDA cells in part
by suppressing the translation of the mRNA encoding glucose
transporter SLC2A6. As a consequence, CR-31 inhibition of
SLC2A6 translation blunts the compensatory glycolytic program
that is normally engaged by cancer cells subjected to ETC
inhibition36.
CR-31 induces a dependency on reverse glutaminolysis. As
described above, CR-31 treatment of PDA cells inhibits translation
of multiple factors implicated in oxidative phosphorylation and
glycolysis. However, polysome proﬁling also identiﬁed a distinct
subset of mRNAs that are translationally upregulated upon CR-31
treatment in KP organoids (Fig. 2c). While many of these mRNAs
are involved in diverse developmental processes, we noted that
some of these transcripts encode enzymes involved in glutamine
transport, such as Slc1a540, and glutamine metabolism, such as
Gls141. Indeed, quantitative RT-PCR conﬁrmed an increase in the
association of these mRNAs with polysomes upon 1 h of CR-31
treatment in KP but not in N organoids (Fig. 6a). Consistently,
expression of the GLS1 protein is increased in patient-derived
PDA cell lines upon CR-31 treatment (Fig. 6b).
We observed that CR-31 increases the intracellular levels of
glutamine in a panel of patient-derived PDA cell lines (Fig. 6c),
likely due to translational upregulation of its transporter SLC1A5
(Fig. 6a). To better understand the metabolic fate of glutamine
upon eIF4A inhibition, we cultured PDA cells in 13C5 glutamine-
containing media for 2 h and quantiﬁed downstream metabolites
using GC/MS. As described earlier, CR-31 treatment targets the
synthesis of ETC components to compromise oxidative mito-
chondrial function (Fig. 4a). Consistent with this, we noted a
decrease in oxidative labelling of metabolites downstream of
glutamine, including malate, fumarate, and aspartate (Fig. 6d).
However, we found a signiﬁcant increase in reductive labelling of
citrate and cis-aconitate from 13C5 glutamine in both CR-31-
treated human (Fig. 6e) and murine PDA cells (Fig. 6f), reﬂecting
a shift towards reductive carboxylation, during which glutamine-
derived α-ketoglutarate is carboxylated to produce isocitrate/
citrate, which is then cleaved to generate oxaloacetate and acetyl-
CoA42. Notably, this shift to reductive carboxylation was not
observed in N organoids given the same treatment (Fig. 6f). The
pathway of reductive carboxylation engages NADPH-dependent
isocitrate dehydrogenase, and subsequent metabolism of
glutamine-derived citrate provides both the acetyl-CoA for lipid
synthesis and the four-carbon intermediates needed to produce
the remaining TCA metabolites and related macromolecular
precursors43. This reductive, glutamine-dependent pathway has
been shown to be the dominant mode of metabolism in rapidly
growing malignant cells containing mutations in ETC complexes
I or III, and in cells with normal mitochondria subjected to acute
pharmacological ETC inhibition44.
The increased glutamine reductive carboxylation of CR-31-
treated cells prompted us to ask if combined inhibition of eIF4A
and glutamine metabolism might represent a more effective
therapeutic strategy than eIF4A inhibition alone. Indeed, we
found that the glutaminase inhibitors BPTES45 and CB83946
(Fig. 6g, h) readily sensitize PDA cells to CR-31. Gemcitabine,
one of the main chemotherapeutics used to treat pancreatic
cancer, did not elicit the same effect (Supplementary Fig. 12a),
demonstrating the selective sensitivity of CR-31-treated cells to
the inhibition of glutaminase. Given that glutamine is a precursor
for glutathione synthesis47, and that CR-31 treatment perturbs
glutathione metabolism (Fig. 3), we initially asked whether
glutaminase inhibition sensitized PDA cells to CR-31 through
further induction of oxidative stress. However, CB839 treatment
did not increase ROS levels (Supplementary Fig. 12b) or NADP+
to NADPH ratios (Supplementary Fig. 12c) above those induced
by CR-31 alone. Accordingly, the ROS scavenger NAC failed to
mitigate the heightened sensitivity of PDA cells to CR-31 by
CB839 (Supplementary Fig. 12d). Given that glutamine-derived
citrate, in the process of reductive carboxylation, provides acetyl-
CoA for lipid synthesis43, we tested the effect of Orlistat, a fatty
acid synthesis inhibitor48, and surprisingly found that it was able
to weakly sensitize patient-derived PDA cell lines to CR-31
(Supplementary Fig. 12e). These results suggest that the
sensitization of PDA cells to CR-31 through co-suppression of
glutaminase activity occurs through redox-independent mechan-
isms, possibly by reducing carbon ﬂow towards fatty acid
synthesis. Using PDA organoid/cancer-associated ﬁbroblast co-
cultures, we observed a therapeutic synergy between CR-31 and
CB839 (Fig. 6i). In vivo, combined inhibition of eIF4A and
glutaminase exhibited an additive effect and suppressed pancrea-
tic tumour growth in an orthotopic transplant model (Supple-
mentary Fig. 12f). Together, these data reveal that eIF4A is critical
for PDA maintenance and delineate an eIF4A-dependent
translation program that promotes redox and central carbon
metabolism in pancreatic cancer cells.
Discussion
Since cancer cells often acquire an aberrantly activated transla-
tional state, inhibition of translation initiation should target
neoplastic cells with limited toxicity for normal cells22. Indeed,
our previous work demonstrated that protein synthesis is elevated
in pancreatic cancer cells in a redox-dependent manner6. How-
ever, the full repertoire of mRNAs which are translationally
altered by oncogenic signalling and the underlying molecular
mechanisms that govern their translational control remain poorly
understood. In this study, we demonstrate that PDA cells have a
heightened dependency on the function of RNA helicase eIF4A.
Moreover, using transcriptome-wide polysome proﬁling, we
uncovered an oncogenic translation program composed of a
speciﬁc subset of transcripts that are sensitive to eIF4A avail-
ability, and can be suppressed upon treatment with the rocaglate
CR-31.
While ours and previous studies24,49,50 support the notion that
modulation of eIF4A activity leads to selective effects on trans-
lation, the underlying mechanisms are still incompletely under-
stood. It has been suggested that G-quadruplexes in 5‵-UTRs
mediate selective suppression of translation downstream of eIF4A
inhibition by the rocaglate silvestrol50, while eIF4A clamping to
polypurine sequences underlie the effects of the rocaglate Roca-
glamide A24. Our ﬁndings suggest that in PDA cells slightly
shorter 5′-UTRs with more stable secondary structures contribute
to the selective suppression of translation following CR-31
treatment. Importantly, we observed that shRNA depletion of
eIF4A phenocopies the metabolic changes induced by CR-31. In
conjunction with our ﬁnding that polypurine sequences are not
enriched in mRNAs translationally suppressed by CR-31, we
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conclude that eIF4A clamping on polypurine sequences cannot
account for the full effect of CR-31 on translatomes observed
herein. Instead, ours and previous studies collectively indicate
that rocaglates act via multiple mechanisms in a drug and/or
context-dependent manner. This is further supported by our
observation that the impact of CR-31 is much more potent on the
translatome of KP organoids than their normal counterparts. The
heightened sensitivity of the PDA translatome to CR-31 may also
reﬂect transcriptional differences between PDA cells and normal
ductal cells, which in turn alter the ability of speciﬁc mRNAs to
compete for access to limiting amounts of eIF4F.
In this study, we found that the functional gene classes whose
translation are strongly dependent on eIF4A in PDA include
those involved in central carbon metabolism. As ﬁrst described by
Otto Warburg, cancer cells often exhibit a high rate of glycolysis.
Recent work further emphasizes that, in addition to a strong
dependence on glycolysis, many tumours, including PDA, also
rely on mitochondrial respiration for bioenergetic51–53 and bio-
synthetic processes54–56. These observations have prompted the
use of biguanides such as Metformin, which can inhibit complex I
of the ETC, as a therapeutic strategy for pancreatic cancer57.
However, Metformin yielded disappointing results in a placebo-
controlled clinical trial in pancreatic cancer58. Interestingly,
Metformin has been shown to increase glycolysis even in cancer
cells that are already highly glycolytic59, thus attenuating its anti-
neoplastic activity. Our study reveals an oncogenic translation
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program supporting both oxidative phosphorylation and glyco-
lysis in pancreatic cancer cells. As such, inhibition of this trans-
lation program using CR-31 inhibits both oxidative
phosphorylation and glycolysis in PDA cells to effectively induce
energy crisis and cell death. Thus, this compound overcomes the
limitations of metabolic inhibitors such as biguanides by blunting
the compensatory increase in glycolysis.
We observed that the suppression of glycolysis by CR-31
occurs at the level of glucose uptake. Elevated glucose uptake in
cancer cells is traditionally attributed to the glucose transporters
SLC2A1 and SLC2A339. In fact, an earlier study using the roca-
glate RHT also reported suppression of glucose transport through
increased TXNIP mRNA levels in cancer cells60, which acts as a
negative regulator of SLC2A161. However, we observed no mea-
surable change in SLC2A1 expression upon CR-31 treatment.
Instead, we show that translation of the mRNA encoding a less
characterized glucose transporter, SLC2A6, is suppressed by CR-
31. This suggests that cancer cells may utilize non-canonical
means of glucose uptake to sustain anabolic needs. While genetic
knockout of this transporter in mice has minimal effect on whole
body metabolic physiology62, the expression of this transporter
has been reported to be elevated in various cancers, including
PDA63,64. In this study, we show that genetic targeting of SLC2A6
expression reduces both glucose uptake and glycolysis, supporting
a functional role for SLC2A6 in PDA glucose metabolism. Our
study suggests that SLC2A6 contributes in part to the glycolytic
defects that arise from pharmacological inhibition of eIF4A in
pancreatic cancer cells. Thus, further characterization of the
contribution of SLC2A6 to glucose uptake relative to SLC2A1/3
may illuminate our understanding of cancer cell metabolism.
It is interesting to note that suppression of eIF4A by CR-31 is
also associated with increased translation of a subset of mRNAs.
While similar observations have been reported in prior studies
involving genetic or pharmacological perturbations of the eIF4F
complex26,30,49,50, the functional relevance of these changes
remains poorly understood. Here, we show that some transcripts
that are translationally activated upon CR-31 treatment may
constitute a metabolic compensatory mechanism to increase
glutaminolysis through the reductive pathway in PDA cells. This
intriguing observation supports the possibility that metabolic
plasticity can occur at the level of translation. While examples of
transcriptional adaptation and genetic compensation are well
documented in the literature, little is known about such com-
pensatory mechanisms at the level of translation, particularly in
the context of tumour stress responses. These ﬁndings add an
important dimension to the mechanisms by which KRAS drives
tumorigenesis. In summary, we have delineated the importance of
eIF4A in the translational control of pancreatic tumour
metabolism and illustrated how this dependency can be ther-
apeutically exploited.
Methods
Animals. Trp53+/LSL-R172H, Kras+/LSL-G12D, Pdx1-Cre, and Nrf2–/– strains in
C57Bl/6J background were interbred to obtain Pdx1-Cre; Kras+/LSL-G12D; Trp53
+/LSL-R172H (KPC)4 or Pdx1-Cre; Kras+/LSL-G12D; Trp53+/LSL-R172H; Nrf2–/–
(KPCn) mice for therapeutic studies and for organoid isolation. C57Bl/6J mice
were purchased from the Jackson Laboratory for the isolation of N organoids. All
animal experiments were conducted in accordance with procedures approved by
the IACUC at Columbia University (AC-AAAT7469).
Human specimens. All human experiments were approved by the ethical com-
mittee of Columbia University (IRB-AAAR6773). Written informed consent from
the donors for research use of tissue in this study was obtained prior to acquisition
of the specimen. Samples were conﬁrmed to be tumour or normal based on
pathological assessment.
Chemical reagents. The rocaglate (-)-CR-1-31-B (bioactive enantiomer) was
synthesized as previously described16.
Orthotopic engraftment in the pancreas. Mice were anesthetized using iso-
ﬂurane, and Ketoprofen/Carprofen (5 mg kg–1), which was subcutaneously admi-
nistered. 2 × 2 mm tumour pieces derived from KPC were transplanted per
pancreas. The abdominal wall was sutured with absorbable vicryl sutures (Ethicon
Cat# J392H), and the skin was closed with wound clips (CellPoint Scientiﬁc Inc.
Cat# 203-1000).
Therapeutic intervention studies in mice. Upon detection of a mass during
weekly palpation, KPC or allograft-bearing mice were subjected to high-contrast
ultrasound imaging using the Vevo 2100 System with a MS250, 13–24MHz
scanhead (Visual Sonics, Inc, Amsterdam, NL). Mice with tumour diameters of
7–9 mm were randomized and enroled one day after scanning. CR-31 was for-
mulated in 5.2% PEG-400 (Sigma-Aldrich Cat# 1546445)/5.2% Tween80 (Sigma-
Aldrich Cat#P4780) in saline. Mice were administered vehicle, 0.2 mg kg−1 CR-31
(intraperitoneal injection, daily) and/or 200 mg kg−1 CB839 formulated in 25%
hydroxypropyl-β-cyclodextrin (Roquette Cat#3461111) (oral gavage, twice daily).
Tumour volume was monitored on days 4 and 7 after initial scan. The same dosing
regimen was applied to C57Bl/6 J mice bearing orthotopic mouse tumour
allografts.
Assessment of CR-31 in vivo toxicity. Gender-balanced C57Bl/6J mice were
randomized and enroled into study. CR-31 was formulated in 5.2% PEG-400/5.2%
Tween80 in saline. Mice were administered vehicle or 0.2 mg kg−1 CR-31 (intra-
peritoneal injection) once per day over 12 days. Body weight of each mouse was
recorded prior to every dose. Mice were euthanized 2 h after the last treatment. Full
necropsy was performed on the mice, organs were embedded in parafﬁn and
sectioned and stained for H&E to look for any abnormalities. Blood was collected
through cardiac puncture into a multivette to isolate plasma (Braintree Scientiﬁc
Cat# MV-600 151673) for measurement of circulating aspartate aminotransferase
(AST), alanine aminotransferase (ALT), amylase, and lipase levels. For accurate
measurements, plasma was diluted in saline, 1:5 dilution for AST and ALT assays,
and 1:2 dilution for amylase and lipase assays. AST, ALT, amylase, and lipase
assays were run on the Element DC machine (Heska).
Fig. 6 CR-31 treatment increases reverse glutamine metabolism in pancreatic cancer cells. a Levels of transcripts encoding proteins involved in glutamine
metabolism in light (<3 ribosomes) or heavy (≥3 ribosomes) polysome fractions from N or KP organoids treated with 10 nM CR-31 for 1 h relative to
vehicle (DMSO). Data are mean+/– S.D., n= 6. Data from two biological replicates are shown. b Immunoblot analysis of GLS in patient-derived PDA cell
lines upon treatment with vehicle or CR-31 for 5 h. VINCULIN, TUBULIN, loading controls. c Intracellular levels of glutamine at steady state from 3 patient-
derived PDA cell lines (2 technical replicates each) treated with vehicle or 100 nM CR-31 for 5 h. Data are mean+/– S.D., Student’s paired t-test. d 13C5-
glutamine tracing of 4 patient-derived PDA cell lines upon treatment with vehicle or 100 nM CR-31 for 5 h. Data are mean+/– S.D., Student’s paired t-test.
Right, schematic illustrating the ﬂow of heavy carbons through glutamine metabolic pathways. e 13C5-glutamine tracing of 4 patient-derived PDA cell lines
upon treatment with vehicle or 100 nM CR-31 for 5 h. M+ 4 indicates metabolites of oxidative glutaminolysis and M+ 5 indicates metabolites of reductive
glutaminolysis. Data are mean+/– S.D., Student’s paired t-test. f 13C5-glutamine tracing of N (n= 2) and KP (n= 2) organoids upon treatment with vehicle
or 100 nM CR-31 for 5 h. Data are mean+/– S.D., Student’s t-test. g Cell viability of patient-derived PDA lines upon a 72 h treatment with increasing
concentrations of CR-31 and the indicated concentrations of the glutaminase inhibitor BPTES (n= 5) or CB839 (n= 3). Data are mean+/– S.D., Student’s
t-test, *p < 0.05 compared to CR-31 only treatment. h Cell viability of KP organoids upon a 72 h treatment with increasing concentrations of CR-31 and the
indicated concentrations of CB839. Dotted lines indicate 95% conﬁdence intervals, n= 5. i KP organoids (GFP-labelled) in co-culture with pancreatic
cancer-associated ﬁbroblasts (mCherry-labelled) upon a 72 h treatment with CR-31 in the presence or absence of CB839. Representative images from two
biological replicates. Scale bars, 1000 μm. Source data are provided as a Source Data ﬁle
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Organoid isolation and culture. Detailed procedures to isolate and propagate
murine and human, normal and neoplastic pancreatic organoids have been
described previously5,65. In brief, organoids were maintained in complete organoid
media: Advanced DMEM/F12 (Gibco Cat#12634010) supplemented with 1%
Penicillin/Streptomycin (PS), 1x GlutaMAX (Gibco Cat# 35050061), 1x Hepes
(Gibco Cat# 15630080), 1x B27 (Invitrogen Cat# 17504044), 1.25 mM N-
Acetylcysteine (NAC) (Sigma-Aldrich Cat# A9165), 10 nM gastrin (Sigma-Aldrich
Cat# G9145), 50 ng/ml EGF (PeproTech Cat# 315-09), 10% RSPO1-conditioned
media, 20% Noggin-conditioned media, 100 ng/ml FGF10 (PeproTech Cat# 100-
26), and 10 mM Nicotinamide (Sigma-Aldrich Cat# N0636). To passage, organoids
were washed out from the GFR-Matrigel (Corning Cat# 356231) using cold
Advanced DMEM/F12 supplemented 1% PS, 1x GlutaMAX and 1x Hepes, and
mechanically dissociated into small fragments using ﬁre-polished glass pipettes,
and then seeded into fresh GFR-Matrigel. Passaging was performed at a 1:4 split
ratio roughly twice per week. All experiments described were done in the absence
of EGF and NAC6. Human cultures were characterized by sequencing DNA to
conﬁrm that they harbour loci representative of human PDA, and the mouse
organoids were genotyped to ensure they carry mutant alleles of Kras, Trp53 and/or
Nfe2l2. Once the cells are cultured in our laboratories, they are regularly screened
for mycoplasma contamination and authenticated by short tandem repeat (STR)
analysis to identify misidentiﬁed, cross-contaminated, or genetically drifted cells.
Cell culture conditions for monolayer cultures. Monolayer KPC primary pan-
creatic cancer cells, patient-derived pancreatic cancer cells, and murine cancer-
associated ﬁbroblasts (CAFs) were cultured in DMEM (Gibco Cat#11995073)
supplemented with 10% fetal bovine serum (FBS) (Corning Cat# 35-010-cv) and
1% PS (Gibco Cat# 15140163). All cells were cultured at 37 °C with 5% CO2.
Co-culture conditions. For co-cultures, GFP-labelled murine organoids were split
at a 1:2 ratio and mixed with 1 × 104 mCherry-labelled CAFs, seeded in 50 μl GFR-
Matrigel, and cultured in DMEM supplemented with 10% FBS and 1% P/S.
Therapeutic experiments with organoids. CR-31, CB839 (Selleckchem Cat#
S7655), and Orlistat (Selleckchem Cat# S1629) were dissolved in DMSO (Sigma-
Aldrich Cat# D2650). The ﬁnal concentration of DMSO was no higher than 0.2%.
Buthionine sulfoximine (Sigma-Aldrich Cat# B2640) was dissolved in PBS. Nine
different doses and a vehicle were used for the cytotoxicity assays for CR-31 as
indicated in each ﬁgure legend. When CR-31 was used in combination with CB839,
the dose of CB839 was ﬁxed to 1, 5 or 10 μM. When CR-31 was used in combi-
nation with Orlistat, the dose of Orlistat was ﬁxed to 50 μM. When CR-31 was used
in combination with BSO, the dose of BSO was ﬁxed to 100 μM. For IC50 analysis,
organoids were dissociated to single cells by triturating organoids in media through
a ﬁre-polished glass pipette, and then by enzymatic dissociation with 2 mgml−1
dispase (Gibco Cat# 17105041) dissolved in TrypLE (Life Technologies Cat#
12604013) at 37 °C, until the organoids appeared as single cells under the micro-
scope (~15 min). Cells were counted, and diluted to 30 cells µl−1 in a mixture of
complete media minus EGF and NAC, and GFR-Matrigel (10% ﬁnal concentra-
tion). 100 µl of this mixture (3000 cells per well) was plated in a 96 well plate
(Corning Cat# 3917) previously coated with a bed of GFR-Matrigel (20 µl per well,
1:1 PBS mixture). Once organoids reformed (between 24–36 h post-plating, con-
ﬁrmed by microscopy), drugs were added in 100 µl of media. As described above,
nine different doses plus a vehicle control were used for each drug, and at least ﬁve
replicate wells were treated with each dose. 72 h after the addition of the drug, cell
viability was measured by area covered using CellInSight CX5, or using a lumi-
nescence ATP-based assay (CellTiter-Glo, Promega Cat# G7573) with a plate
reader (SpectraMax i3x, Molecular Devices).
Analysis of global protein synthesis. Isotope labelling: Organoids were incubated
for 30 min in media containing 10 μCi of [35S] labelled Methionine (Perkin Elmer
Cat# NEG709A005MC). For liquid scintillation, equal amounts of radiolabelled
total protein were TCA-precipitated and washed two times in acetone and air dried
at room temperature. The amount of [35S]-Met incorporated into protein was
measured using a Beckman LS6500 Scintillation counter. Total protein content was
determined by BCA assay (Bio-Rad Cat# 5000116).
O-propargyl-puromycin labelling: Click-iT assays were performed using 1 × 106
cells per assay according to the manufacturer’s protocol. In brief, O-propargyl-
puromycin (OP-Puro; 20 μM) (Life Technologies Cat# C10456,) was added to the
cells and incubated for 30 min. Cells were washed in ice-cold PBS and then ﬁxed
and permeabilized. The amount of alexa-Fluor-488 conjugated OP-Puro was
quantiﬁed using ﬂow cytometry using a BD LSR Fortessa Cytometer (BD
Biosciences). Data analysis was performed using FlowJo v9.7.6 (FlowJo, Ashland,
RRID:SCR_008520).
SUnSET (Surface Sensing of Translation) assay. The in vivo SUnSET assay was
adapted from a published protocol20. Puromycin (40 nmol g−1 body weight)
(Sigma-Aldrich Cat# P9620) was injected intraperitoneally in mice 30 min prior to
their sacriﬁces. The pancreas was then removed, ﬁxed in 10% formalin for one day,
embedded in parafﬁn and sliced. Immunohistochemistry was performed using
1:1000 dilution of the anti-puromycin 12D10 antibody (Millipore Cat# MABE343,
RRID:AB_2566826).
Polysome fractionation and qRT-PCR. Organoids were treated with vehicle or
10 nM CR-31 for 1 h. In the ﬁnal 5 min, 100 μg ml–1 of Cycloheximide was sup-
plemented into the media. The organoids were then harvested on ice in PBS
containing 100 μg ml–1 Cycloheximide. Cells were pelleted and lysed in 10 mM
Tris-HCl (pH 8), 140 mM NaCl, 1.5 mM MgCl2, 0.25% NP-40, 0.1% Triton X-100,
50 mM DTT, 150 μg ml–1 Cycloheximide, and 640 Uml–1 RNasin (Sigma Cat#
3335399001) for 15 min. Lysates were cleared, and then loaded onto a 10–50%
sucrose gradient made using a Biocomp Gradient Master 108 and centrifuged for
2 h and 15 min at 151,263 × g in a SW41 rotor using a Sorvall Discovery 90SE. The
gradients were fractionated on a Teledyne ISCO Foxy R1 apparatus while mon-
itoring the OD254.
RNA-sequencing and bioinformatics analysis. Fractions corresponding to
mRNA populations bound by ≥3 ribosomes were pooled. RNA was extracted using
TRIzol (Invitrogen Cat# 15596018) according to the manufacturer’s instructions.
Prior to loading of the sample on the sucrose gradient, a fraction of the lysate was
also taken for RNA extraction, corresponding to the total RNA fraction. The RNA
was then submitted to RNA-Seq on an Illumina HiSeq 4000 PE100 at the McGill
University and Genome Quebec Innovation Center.
RNA-Seq reads were subjected to and passed quality control (Phred scores > 30)
and were subsequently aligned to the hg38 reference genome using HISAT2
(version 2.04) with default settings. Reads mapped to multiple locations in the
genome were discarded. Gene expression was quantiﬁed using the RPKMforgenes.
py method (settings -fulltranscript, -onlycoding)66 from which raw gene counts
were obtained (version last modiﬁed 11.04.2013). Genes that could not be resolved
(based on sequence similarity) and/or had 0 counts in at least one sample were
removed from the analysis. Genes were annotated using the RefSeq database. A
total of 11402 unique genes were represented in the RNAseq data. Non-normalized
RNAseq data was used as input in anota2seq (ver. 1.2.0; with parameters datatype
= “RNAseq”, normalize= TRUE, transformation= “TMM-log2”). Changes in
translational efﬁciencies altering protein levels were assessed using the
anota2seqAnalyze function. Contrasts were set to assess the effect of CR-31 in N
organoids, the effect of CR-31 in KP organoids and the difference between non-
treated N and KP organoids. Genes were considered signiﬁcantly regulated when
passing ﬁltering criteria (parameters for anota2seqSelSigGenes function) [maxPAdj
(FDR) <0.25], [selDeltaPT >log2(1.2)], [minSlopeTranslation >−1],
[maxSlopeTranslation <2], [selDeltaTP >log2(1.2)], [minSlopeBuffering >−2] and
[maxSlopeBuffering <1], [selDeltaP >log2(1)], [selDetaT >log2(1)]. Changes in
mRNA abundance were then assessed using the anota2seqRegModes function. 5′-
UTR sequences were obtained from the RefSeq database (mm10)67. If multiple
sequences for a gene were present only the longest was taken into consideration. 5′-
UTR GC content and length were calculated based on the obtained sequences.
Linear regression of 5′-UTR energy ~5′-UTR length was performed to obtain
residuals representing free energy levels of 5′-UTRs adjusted for 5′-UTR lengths.
KEGG pathway68 enrichment analysis was performed using -log10(FDR) * sign
(log2FC) of polysome-associated mRNA changes and the gage R-package32
(version 2.30.0, saaTest= ts.KStest). The datasets generated during and/or analysed
during the current study are available in the GEO repository under the accession
number GSE125380.
RNA-Seq validation. For the RNA-Seq validation, organoids were treated with
CR-31 and polysomes were fractionated as described above. The fractions were
pooled into two groups corresponding to mRNA populations that were bound to
either 3 ribosomes and up or 2 ribosomes or less. The RNA was extracted using
TRIzol and cDNA was made using M-MuLV Reverse Transcriptase (New England
Biolabs Cat# M0253S) and oligo(dT)20 primers. qPCRs were performed with
SsoFast Evagreen Supermix (Bio-Rad Cat# 1725200) using the CFX96 PCR system
(Bio-Rad Cat# 1855195). The following primers were used: Gls1: For: 5′ GGGCA
TGATGTGTTGGTCTC 3′, Rev: 5′ ATGCGGCAAACAGAAGGTTT 3′; Slc1a5:
For: 5′ TTTCAGCCTCCATTCTCGGT 3′ Rev: 5′ TGGAATCCACCGCTACTA
CC 3′; GAPDH: For: 5′ AACGGATTTGGCCGTATTGG 3′ Rev: 5′ CATTCTCG
GCCTTGACTGTG 3′; Enolase 2: For: 5′ AGAAGGCCTGCAACTGTTTG 3′ Rev:
5′ TGTACACAGTCCGACGACAA 3′; Enolase 3: For: 5′ GGGTCCCTCTCTAC
CGACAC 3′ Rev: 5′ ATGCGCATGGCTTCCTTGAA 3′; Sdhb: For: 5′ GAATGC
AGACGTACGAGGTG 3′; Rev: 5′ CAAGAGCCACAGATGCCTTC 3′; Ndufa3:
For: 5′ TGCCTTCCTCAAGAATGCCT 3′; Rev: 5′ GCACTGGGTAGTTGTAG
GGT 3′. Slc2a6: 5′ TGTACCGGCCTGTTCTCATT 3′ CCAACTATCGCTGCA
TCCTG. The presence of each mRNA upon CR-31 treatment relative to DMSO in
the two groups was calculated using the ΔCT method.
Flow cytometry. Mitochondrial numbers and cellular ROS: For cellular reactive
oxygen species (ROS) and mitochondrial staining, cells were labelled in phenol-
red-free Advanced DMEM/F12 media containing 10 μM 2′,7′-dichloroﬂuorescein
diacetate (Invitrogen Molecular probes Cat# C6827) or 100 nM Mito-tracker Green
FM (Cell Signalling Technology Cat# 9074), respectively, for 30 min, and analysed
by ﬂow cytometry.
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SLC2A1 surface expression: Dissociated single cells were ﬁxed with 4%
paraformaldehyde at room temperature for 15 min. Cells were incubated with
SLC2A1 antibody (Abcam, Cat# 40084, RRID: AB_2190927), 1:100 dilution in
0.5% BSA/PBS, followed by anti-mouse Alexa Fluor488 (Thermo Fisher Scientiﬁc
Cat# R10477) in 0.5% BSA/PBS, and analyzed by ﬂow cytometry.
Lentiviral and retroviral production and infection. pLenti-Cas9, LRC2.1T-
sgRNA and human pPrime-PGK-Puro shRNA lentiviruses were produced in 293
T cells co-expressing the packaging vectors (pPAX2, Addgene# 12260 and VSVG,
Addgene# 12259), concentrated with LentiX concentrator (Clontech Cat# 631232),
and resuspended with DMEM supplemented with 10%FBS and 1% PS at 5×
concentration. Mouse MLS shRNA retroviruses were produced in Phoenix-ECO
cells (ATCC Cat# CRL-3214, RRID:CVCL_H717), concentrated with RetroX
Concentrator (Clontech Cat# 631456), and resuspended in DMEM supplemented
with 10% FBS and 1% PS, or Advanced DMEM/F12 (Gibco Cat#12634010) sup-
plemented with 1% Penicillin/Streptomycin (PS), 1× GlutaMAX (Gibco Cat#
35050061), and 1× Hepes (Gibco Cat# 15630080) at 5× concentration. To knock-
down the expression of eIF4A1, short hairpin RNAs against eIF4A1 were used. For
mouse cell lines, shRenilla was used as a control, while sheIF4A1.371 (5′-ATTGA
TATGGCAAATGTAGCTG-3′) and sheIF4A1.372 (5′-AATTGATATGGCAAAT
GTAGCT-3′). For human cell lines, shRenilla was used as a control, and
sheIF4A1.969 was used to knockdown eIF4A1 (5′-TCGAGCATGCATCTTCTCG
GTG-3′). Two hundred thousand cells were plated and infected with 5× con-
centrated virus with 5 μg ml−1 polybrene (Millipore Sigma Cat# TR1003G) and
spinoculated at 600 RCF for 45 min at room temperature. For organoids, spino-
culated cells were kept at 37 °C with 5% CO2 for 6 h prior to replating in Matrigel
and organoid media. One day after infection, pPrime-PGK-Puro shRNA infected
cells were treated with 2 μg ml−1 puromycin (Sigma-Aldrich Cat# P9620) for
selection.
CRISPR/Cas9-mediated gene deletion. Organoid lines were transduced with
lentivirus expressing Cas9 (EFS-Cas9-P2A-Puro, Addgene: 108100). In this study,
all sgRNAs targeting mouse genes were cloned into LRC2.1T (U6-sgRNA-Cherry,
Addgene# 108099). Single sgRNAs were cloned by annealing two DNA oligos and
T4 DNA ligation into a BsmB1-digested LRC2.1T69. To improve U6 promoter
transcription efﬁciency, an additional 5′ G nucleotide was added to all sgRNA oligo
designs that did not already start with a 5′ G. gRNA sequences used to target Slc2a6
are: CACCGAGCTGACTCCGAGGTCCAT and CACCGCACGGATGTGTTGTC
GAAGA. gRNA sequence against the ROSA locus was used as a negative control:
GAAGATGGGCGGGAGTCTTC.
Protein puriﬁcation and ﬂuorescence polarization. eIF4AI was expressed in E.
coli BL21 cells and puriﬁed by Ni-NTA agarose and Q-Sepharose chromatography.
Fluorescence polarization was performed by incubating 1 µM eIF4AI in ﬂuores-
cence polarization buffer (14.4 mM HEPES-NaOH, 108 mM NaCl, 1 mM MgCl2, 1
mM DTT, 14.4% glycerol and 0.1% DMSO, pH 7.5) in presence of either 1 mM
ATP or AMP-PNP, 10 nM 5’-FAM-labelled (AG)10 RNA and 50 µM CR-31 for
30 min at 25 °C. After incubation, the FAM-labelled RNA was chased with 100 µM
unlabelled poly (AG)10 RNA. For the combination of ATP and DMSO, 50 μM of
eIF4AI was used instead due to low binding afﬁnity of eIF4A to RNA. Variation in
polarization was determined on a BMG Labtech Pherastar FS and the t1/2 half-life
calculated using one-phase exponential decay equation with Graphpad Prism
software.
Membrane fractionation. Cytoplasmic and membrane protein extracts were
prepared using the Subcellular Protein Fractionation Kit (Thermo Scientiﬁc Cat#
78840). In brief, cytoplasmic extraction buffer provided by the manufacturer was
added to the cell pellet, followed by 15 min of incubation at 4 °C and centrifugation
at 500 × g for 5 min. The supernatant containing the cytoplasmic protein extract
was collected before the addition of membrane extraction buffer provided by the
manufacturer, followed by 15 min of incubation at 4 °C and centrifugation at
3000 × g for 5 min. Supernatant containing the membrane protein extract was
collected.
NADP+/NADPH quantiﬁcation. NADP+/NADPH ratio was quantiﬁed by a luci-
ferase assay provided in the NADP+/NADPH Glo Assay kit (Promega Cat# G9071).
Patient-derived pancreatic cancer cells or murine organoids were plated in their
respective media, incubated in a tissue culture incubator (37 °C, 5% CO2), and were
treated with CR-31, CB839 or BSO. After appropriate treatment over the desired time,
the medium was removed and cells were supplemented with 1:1 PBS and 0.2 N
NaOH solution with 1% DTAB to obtain a cell lysate. To measure NADP+, cell
lysates were treated with 0.4 N HCl and heat quenched at 60 °C for 15min. The
solution was then neutralized with Trizma buffer (Tris base [Fisher Cat# BP152] in
water). To measure NADPH, cell lysates were heat quenched at 60 °C for 15min and
the solution was neutralized with HCL-Trizma (Quality Biological Cat# 351-050-101).
An equal volume of NADP+/NADPH-Glo Detection Reagent was added to each well
with cell lysate, incubated at room temperature for 30min, and luminescence was
read on a luminometer (Spectramax i3x, Molecular Devices).
Glucose Uptake Glo. Glucose Uptake was measured using the Glucose Uptake-Glo
Assay kit (Promega Cat# J1341). Cells were incubated in a tissue culture incubator
(37 °C, 5% CO2), and were treated with CR-31. After 5 h of treatment, the medium
was replaced with PBS, and treated with 1mM 2-deoxyglucose for 10 min. Stop
Buffer, Neutralization Buffer, and 2DG6P Detection Reagent provided by the
assay kit were subsequently added, incubated at room temperature for 30min.
Luminescence was read on a luminometer (Spectramax i3x, Molecular Devices).
Metabolomics: Cell treatment and harvest.
1. Organoids: One million cells were grown as organoids in ten 50 μl Matrigel
domes in a 10 cm plate, cultured in EGF and NAC-free complete media and
harvested at steady state or after treatment with DMSO or 100 nM CR-31
for 5 h. Spent media was collected at the end of the 5 h for metabolite
analysis. For tracing experiments, 13C6-Glucose (17.5 mM) or 13C5-
Glutamine (2 mM)-containing media (SITA media) was used to replace
12C media in the ﬁnal 2 h. Organoids were collected on ice in 2 ml Cell
Recovery Solution (Corning Cat# 354253) to remove Matrigel, triturated
through a ﬁre-polished glass pipette, and then washed with ice cold saline (9
g NaCl per litre). All saline was aspirated and discarded. The resultant pellet
was immediately quenched with 1 ml −20 °C pre-chilled 80% methanol (v/
v) and ﬂash frozen on dry ice and stored at −80 °C until the day before GC/
MS analysis.
2. Monolayer cells: One million patient-derived PDA cells were grown in
DMEM supplemented with 10% dialyzed FBS (Gibco Cat# 26400044) and
1% PS, and treated with DMSO or 100 nM CR-31 for 5 h. For tracing
experiments, 13C6-Glucose (17.5 mM) or 13C5-Glutamine (2 mM)-contain-
ing media (SITA media) was used to replace 12C media in the ﬁnal 2 h.
Spent media was collected at the end of the 5 h for metabolite analysis. Cells
were rinsed with 10 ml of ice-cold saline (9 g NaCl per litre). All saline was
aspirated and discarded. Cells were immediately quenched with 1 ml −20 °C
pre-chilled 80% methanol (v/v), scraped and ﬂash frozen on dry ice and
stored at −80 °C until the day before GC/MS analysis.
Metabolomics: stable isotope tracer analysis. Sample extraction and GC/MS
analysis were carried out as follows. Samples were subjected to sonication using
BioRuptor (Diagenode Cat# UCD-200 TM,) for 10 min (30 s ON, 30 s OFF) at the
“high” setting. Cellular debris was removed by centrifugation (10 min, 19,500 × g,
1 °C). Supernatants were transferred to fresh pre-chilled tubes containing 1 ml of
750 ng/ml D27-myristic acid internal standard. Samples were subsequently dried
overnight at −4 °C using a temperature controlled vacuum centrifuge (Labconco,
Kansas City, MO, USA).
In order to protect and stabilize α-keto acids (pyruvate, α-ketoglutarate etc.),
dried sample pellets were resuspended in 30 μl pyridine containing 10 mgml−1
methoxyamine hydrochloride (Sigma Cat# 226904), vortexed, and sonicated to
ensure dissolution. Following 30 min of incubation at room temperature, samples
were transferred to sealed autoinjection vials containing 70 μl of N-tert-
Butyldimethylsilyl-N-methyltriﬂuoroacetamide (MTBSTFA) (Sigma Cat# M-108).
Vials were incubated for 1 h at 70 °C.
Derivatized samples were subjected to GC/MS analysis using an Agilent 5975 C
GC/MS equipped with a DB-5MS+DG (30 m × 250 µm × 0.25 µm) capillary
column (Agilent J&W, Santa Clara, CA, USA). All samples were injected three
times: twice using scan (50–700m/z) mode (1× and 6× dilution) and once using
selected ion monitoring (SIM) mode. One microlitre of the derivatized sample was
injected in the GC in splitless mode with inlet temperature set to 280 °C and
electron impact set at 70 eV. Helium was used as the carrier gas with a ﬂow rate
such that myristic acid eluted at approximately 18 min. The quadrupole was set at
150 °C and the GC/MS interface at 285 °C. The oven program started at 60 °C held
for 1 min, then increasing at a rate of 10 °Cmin−1 until 320 °C. Bake-out was at
320 °C for 10 min. All metabolites used in this study were previously validated
using authentic standards to conﬁrm mass spectra and retention times. Integration
of ion intensities (generally M-57 ion) was done using the Agilent Mass Hunter
Quant software (Agilent Technologies). Mass isotopomer distribution analysis was
carried out using an in-house algorithm adapted from ref. 70.
Metabolomics: extracellular analysis. Spent media were collected from cultured
cells and clariﬁed by centrifugation for 10 min at 1 °C at 19,500 × g. Supernatants
were submitted to the BioProﬁle 400 analyzer (Nova Biomedical Canada, Ltd.
Mississauga, Ontario) for quantiﬁcation of extracellular glucose and lactate.
Extracellular acidiﬁcation rates measurement (ECAR). Ten thousand cells were
plated as organoids in 2 μl Matrigel domes or directly in monolayer in XF96 cell
culture microplates (Seahorse Biosciences, Cat#101104-004) in EGF and NAC-free
organoid complete media (for organoids) or DMEM supplemented with 10% FBS (for
monolayer cells). After 24 h, growth media was changed to bicarbonate-free assay
media (XF assay medium, Seahorse Biosciences, Cat#102365-100) and incubated at
37 °C for 1 h in a CO2-free incubator. Extracellular acidiﬁcation rate (ECAR) was
measured using an XF96 Extracellular Flux Analyzer (Seahorse Biosciences) under
basal conditions and following addition of glucose (10mM), Oligomycin (1 μM), and
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the glucose analog, 2-deoxyglucose, 2DG (50mM), according to the manufacturer’s
protocol. Treatment was with vehicle or CR-31 for 5 h.
Oxygen consumption rates measurement (OCR). Ten thousand cells were
plated as organoids in 2 μl Matrigel domes or directly in monolayer in XF96 cell
culture microplates (Seahorse Biosciences, Cat#101104-004) in DMEM supple-
mented with 10% dialyzed FBS (for monolayer cells) or EGF and NAC-free
organoid complete media (for organoids). After 24 h, growth media was changed to
bicarbonate-free assay media (XF assay medium, Seahorse Biosciences,
Cat#102365-100) and incubated at 37 °C for 1 h in a CO2-free incubator. Oxygen
consumption rate (OCR) was measured using an XF96 Extracellular Flux Analyzer
(Seahorse Biosciences) under basal conditions or following the addition of Oligo-
mycin (1 μM), the uncoupler FCCP (0.5 μM), and the electron transport inhibitor
Rotenone/Antimycin A (0.5 μM), according to the manufacturer’s protocol.
Treatment was with vehicle or CR-31 for 5 h.
Quantitative RT-PCR. RNA was extracted from cell cultures using TRIzol reagent
(Invitrogen Cat# 15596018). cDNA was synthesized using 1 μg of total RNA and
TaqMan Reverse Transcription Reagents (Applied Biosystems Cat# N8080234). All
targets were ampliﬁed (40 cycles) using gene-speciﬁc Taqman primers and probe
sets (Applied Biosystems) on a QuantStudio5 Real-time-PCR instrument (Applied
Biosystems). Relative gene expression quantiﬁcation was performed using the
ΔΔCT method with the QuantStudio Real-Time PCR software v1.1 (Applied
Biosystems). Expression levels were normalized to Hprt and Actb.
Taqman probes used:
HPRT Mm00446968_m1, Hs02800695_m1
ACTB Hs99999903_m1
NQO1 Hs01045994_m1
HMOX1 Hs01110250_m1
ENOLASE1 Hs00361415_m1
HEXOKINASE II Hs00606086_m1
LDHA Hs01378790_g1
SLC2A1 Hs00214042_m1
Slc2a6 Mm00554217_m1
Western blot analysis. Standard techniques were employed for immunoblotting
of organoids. Organoids were quickly harvested using cold PBS on ice. Protein
lysates were prepared using 0.1% SDS lysis buffer in 50 mM Tris pH8, 0.5%
Deoxycholate, 150 mM NaCl, 2 mM EDTA, 1% NP40, with one tablet of Phos-
STOP (Roche Cat# 4906837001) and one tablet of cOmplete™, Mini, EDTA-free
Protease Inhibitor Cocktail (Roche Cat# 11836170001) per 10 ml buffer, and
separated on 4–12% Bis-Tris NuPAGE gels (Invitrogen Cat# NP0335BOX),
transferred onto a PVDF membrane (Millipore Cat# IPVH00010) and incubated
with the following antibodies: TUBULIN (Cell Signalling Technology Cat# 2148,
RRID:AB_2288042); ACTIN (Cell Signalling Technology Cat# 8456, RRID:
AB_10998774), phospho-AKT (Cell Signalling Technology Cat# 4060, RRID:
AB_2315049), pan-AKT (Cell Signalling Technology Cat# 9272, RRID:
AB_329827), phospho-S6 Ribosomal Protein (Cell Signalling Technology Cat#
4858, RRID:AB_916156), S6 Ribosomal Protein (Cell Signalling Technology Cat#
2317, RRID:AB_2238583), 4EBP1 (Cell Signalling Technology Cat# 9452, RRID:
AB_331692), phospho-4EBP1 (Cell Signalling Technology Cat# 3929, RRID:
AB_10695878), eIF4E (Cell Signalling Technology Cat# 2067, RRID:AB_2097675),
phospho-eIF4E (Cell Signalling Technology Cat# 9741, RRID:AB_331677),
SLC2A6 (1:500) (Sigma-Aldrich Cat# HPA042272, RRID:AB_2677924), ENOLASE
1 (Cell Signalling Technology Cat# 3810, RRID:AB_2246524), ENOLASE 2 (Cell
Signalling Technology Cat# 9536, RRID:AB_2099308), ENOLASE 3 (Abcam Cat#
ab96334, RRID:AB_10680754), eIF4A1 (Abcam Cat#31217, RRID:AB_732122),
eEF2 (Abcam Cat# ab75748, RRID:AB_1310165), IGF-IR-Iβ (Cell Signalling Cat#
9750, RRID:AB_10950969), SDHB (Abcam Cat # ab14714, RRID:AB_301432),
GAPDH (1:10,000) (Cell Signalling Technology Cat# 2118, RRID:AB_561053),
VINCULIN (Cell Signalling Technology Cat# 4650, RRID:AB_10559207), eIF2α
(Cell Signalling Technology Cat# 5324, RRID:AB_10692650), phospho-eIF2α (Cell
Signalling Technology Cat# 3398, RRID:AB_2096481), SLC2A3 (Santa Cruz Bio-
technology Cat# sc-74399, RRID:AB_1124975), SLC2A4 (Cell Signalling Tech-
nology Cat# 2213, RRID:AB_823508), HEXOKINASE I (Cell Signalling
Technology Cat# 2024, RRID:AB_2116996), HEXOKINASE II (Cell Signalling
Technology Cat# 2867, RRID:AB_2232946), LDHA (Cell Signalling Technology
Cat# 3582, RRID:AB_2066887), mTOR (Cell Signalling Technology Cat# 2983,
RRID:AB_2105622), phospho-mTOR (Cell Signalling Technology Cat# 5536,
RRID:AB_10691552), PFKP (Cell Signalling Technology Cat# 8164, RRID:
AB_2713957), PKM2 (Cell Signalling Technology Cat# 4053, RRID:AB_1904096),
Pyruvate Dehydrogenase (Cell Signalling Technology Cat# 3205, RRID:
AB_2162926), SLC2A1 (Cell Signalling Technology Cat# 12939, RRID:
AB_2687899), Glutaminase (Abcam Cat# ab93434, RRID:AB_10561964 and Pro-
teintech Group Cat#12855-1-AP, RRID:AB_2110381), KRAS (Abcam Cat#
ab180772), AMPK (Cell Signalling Technology Cat# 2793, RRID:AB_915794),
phospho-AMPK (Cell Signalling Technology Cat# 2535, RRID:AB_331250),
afﬁnity-puriﬁed rabbit-anti-full-length mouse NRF2 antibody (1:500) (made by JR
Prigge, Montana State University) was a provided by Dr. Ed. Schmidt (Montana
State University). All immunoblots are representative of at least three experiments.
All antibodies were used at 1:1000 dilution unless stated otherwise.
Immunohistochemistry. Tissues were ﬁxed in 10% neutral buffered formalin and
embedded in parafﬁn. Sections were subjected to H&E staining as well as immu-
nohistochemical staining. Antigen retrieval was done in 10 mM citrate buffer (pH
6). The following primary antibodies were used for immunohistochemical staining
at the indicated dilution: phospho-Histone H3, 1:200 (Cell Signalling Technology
Cat# 9701, RRID:AB_331535), c-MYC, 1:400 (Abcam Cat# ab32072, RRID:
AB_731658), cleaved caspase 3, 1:200 (Cell Signalling Technology Cat# 9664,
RRID:AB_2070042).
Tumour bioluminescent and FDG-PET imaging analysis. Athymic nude mice
(Charles River) were orthotopically transplanted with luciferase-expressing pan-
creatic cancer cells. Upon detection of a mass by palpation, mice were subjected to
bioluminescent imaging using the IVIS spectrum (PerkinElmer Cat# 124262). Mice
were injected with 150 mg kg−1 D-Luciferin (Goldbio Cat# LUCK) to ensure
similar tumour volume (determined by total ﬂux). Mice were randomized and
enrolled one day after scanning. CR-31 was formulated in 5.2% PEG-400/5.2%
Tween80 in saline. Mice were imaged once using FDG-PET, followed by treatment
with vehicle or 0.2 mg kg−1 CR-31. Sixteen hours after the ﬁrst image, mice were
given a second dose of vehicle or 0.2 mg kg−1 CR-31 and imaged again using FDG-
PET 5 h after.
FDG-PET: 6 h prior to the administration of FDG, animals were deprived of
food with water source remaining. [18F]-FDG was administered by intraperitoneal
injection in a dose of 3.7 MBq per mouse. Approximately 60 min after FDG
administration, static PET images of the whole body were acquired over 20 min
using Inveon D-PET scanner (Siemens) in 2D mode. Immediately after completion
of the pre-treatment/baseline PET scan, treatment was administered to the animals,
as described above. Food was returned to the animals at that point.
Analysis: The images were reconstructed using Inveon software in 2D OSEM
mode with 4 iterations and 128 × 128 matrix. Image analysis was performed on
PBAS software (Pmod Technologies LLC, Zurich, Switzerland). The volumes of
interest were drawn around the tumours in the right side of the abdomen and
around the contralateral thigh muscles. SUVmax values were used for quantitative
analysis. In order to compensate for the metabolic variabilities between the
animals, tumour to muscle ratio was also calculated.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The polysome proﬁle datasets that support the ﬁndings of this study have been deposited
in GEO under the accession number GSE125380. In addition to polysome proﬁling
datasets, all other raw data that support the ﬁndings of this study are also provided in
“Source Data ﬁle”.
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